Leerink Partnrs Analysts Boost Earnings Estimates for XENE

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for Xenon Pharmaceuticals in a report issued on Tuesday, May 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn ($1.10) per share for the quarter, up from their prior forecast of ($1.14). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals' Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.20) EPS and FY2025 earnings at ($4.30) EPS.

A number of other brokerages have also commented on XENE. Royal Bank of Canada decreased their price objective on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Wells Fargo & Company cut their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Chardan Capital reiterated a "buy" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. The Goldman Sachs Group cut their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $54.82.

Xenon Pharmaceuticals Price Performance

XENE traded down $0.84 during trading on Friday, hitting $30.59. The company had a trading volume of 286,277 shares, compared to its average volume of 513,503. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.00. The business has a 50-day moving average of $33.93 and a 200-day moving average of $37.79. The company has a market cap of $2.35 billion, a PE ratio of -10.81 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million for the quarter, compared to analysts' expectations of $1.64 million. During the same period last year, the firm earned ($0.62) earnings per share.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently modified their holdings of XENE. Goldman Sachs Group Inc. boosted its stake in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company's stock valued at $14,854,000 after acquiring an additional 32,486 shares during the last quarter. Granahan Investment Management LLC lifted its holdings in Xenon Pharmaceuticals by 0.8% during the 1st quarter. Granahan Investment Management LLC now owns 183,808 shares of the biopharmaceutical company's stock valued at $6,167,000 after purchasing an additional 1,475 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Xenon Pharmaceuticals by 9.4% during the first quarter. Advisors Asset Management Inc. now owns 14,281 shares of the biopharmaceutical company's stock valued at $479,000 after acquiring an additional 1,233 shares during the period. Alyeska Investment Group L.P. lifted its position in Xenon Pharmaceuticals by 27.1% in the 1st quarter. Alyeska Investment Group L.P. now owns 367,233 shares of the biopharmaceutical company's stock valued at $12,321,000 after acquiring an additional 78,390 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Xenon Pharmaceuticals by 2.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,914,749 shares of the biopharmaceutical company's stock worth $64,240,000 after purchasing an additional 51,276 shares during the period. Hedge funds and other institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.